What is Phi Optics?
Phi Optics is at the forefront of developing advanced imaging technologies for the life sciences sector. Their expertise lies in Quantitative Phase Imaging (QPI), a technique that enhances existing microscopy capabilities to offer superior assay performance without the need for labels. The company's product suite, including CellVista SLIM and GLIM, is designed to empower researchers and institutions by enabling more precise visualization and analysis of cell assays, tissue, and organoids. This focus on label-free, live microscopy facilitates cutting-edge biological research.
How much funding has Phi Optics raised?
Phi Optics has raised a total of $250K across 1 funding round:
Angel/Seed
$250K
Angel/Seed (2013): $250K with participation from Illinois Ventures and Serra Ventures
Key Investors in Phi Optics
Illinois Ventures
Illinois Ventures is a venture capital firm focused on seed and Series A investments in deep tech sectors, particularly those linked to the University of Illinois. They support over 125 companies in fields like engineering, cancer therapeutics, and AI, aiming to foster technological innovation.
Serra Ventures
Serra Ventures is a venture capital firm specializing in early-stage technology startups, with a strong emphasis on the AgTech sector. They manage multiple funds and have backed over 100 startups across the U.S., supporting technological and agricultural innovation.
What's next for Phi Optics?
With the context of large-scale late-stage funding, Phi Optics is positioned for significant expansion and market penetration. This strategic investment likely signals a phase of scaling operations, further product development, and potentially broader commercialization efforts. The company's trajectory suggests a move towards solidifying its position as a key provider of innovative imaging tools for the global life sciences research community, aiming to accelerate discoveries through enhanced visualization capabilities.
See full Phi Optics company page
